Mainz Biomed N.V. (BST: 4TO)

Market Cap	5.45M
Revenue (ttm)	856.03K
Net Income (ttm)	-21.01M
Shares Out	n/a
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	0.221
Previous Close	0.232
Day's Range	0.209 - 0.221
52-Week Range	0.173 - 1.532
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 71
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 4TO

Financial Performance

In 2023, Mainz Biomed's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.

Financial numbers in USD